Literature DB >> 32887953

Determining the reliability of liver biopsies in NASH clinical studies.

Thomas Longerich1, Peter Schirmacher2.   

Abstract

Mesh:

Year:  2020        PMID: 32887953     DOI: 10.1038/s41575-020-00363-8

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.

Authors:  Beth A Davison; Stephen A Harrison; Gad Cotter; Naim Alkhouri; Arun Sanyal; Christopher Edwards; Jerry R Colca; Julie Iwashita; Gary G Koch; Howard C Dittrich
Journal:  J Hepatol       Date:  2020-06-28       Impact factor: 25.083

  1 in total
  3 in total

1.  Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.

Authors:  Jie Chen; Alina M Allen; Terry M Therneau; Jun Chen; Jiahui Li; Safa Hoodeshenas; Jingbiao Chen; Xin Lu; Zheng Zhu; Sudhakar K Venkatesh; Bin Song; Richard L Ehman; Meng Yin
Journal:  Eur Radiol       Date:  2021-08-25       Impact factor: 5.315

2.  Improved pathology reporting in NAFLD/NASH for clinical trials.

Authors:  Caitlin Rose Langford; Marc H Goldinger; Darren Treanor; Clare McGenity; Jonathan R Dillman; Daniela S Allende; Robert Goldin; Elizabeth M Brunt; Kurt Zatloukal; Helmut Denk; Kenneth A Fleming
Journal:  J Clin Pathol       Date:  2021-11-09       Impact factor: 3.411

3.  A robust gene expression signature for NASH in liver expression data.

Authors:  Yehudit Hasin-Brumshtein; Suraj Sakaram; Purvesh Khatri; Yudong D He; Timothy E Sweeney
Journal:  Sci Rep       Date:  2022-02-16       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.